Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia.


Rituximab is an active agent for the treatment of Waldenstrom's macroglobulinemia. However, many patients do not respond to this agent and several others develop secondary resistance. In order to identify clinical and laboratory parameters that could predict a higher likelihood for response, we evaluated 54 patients who were treated with single-agent… (More)


Cite this paper

@article{Dimopoulos2005PredictiveFF, title={Predictive factors for response to rituximab in Waldenstrom's macroglobulinemia.}, author={Meletios Athanasios Dimopoulos and A Anagnostopoulos and Constantinos Zervas and Marie Christine Kyrtsonis and Athanasios Zomas and Constantinos Bourantas and Nicolaos Anagnostopoulos and Gerrassimos Pangalis}, journal={Clinical lymphoma}, year={2005}, volume={5 4}, pages={270-2} }